Evidence-based hyponatremia management in liver disease
Clinical and Molecular Hepatology · 01.10.2023 · 29 (4) · 924-944
DOI: 10.3350/cmh.2023.0090 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2023. Verfasst von Ji Young Ryu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea. Hauptthemen laut MEDLINE: Hyponatremia, Liver Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Hyponatremia is primarily a water balance disorder associated with high morbidity and mortality. The pathophysiological mechanisms behind hyponatremia are multifactorial, and diagnosing and treating this disorder remains challenging. In this review, the classification, pathogenesis, and step-by-step management approaches for hyponatremia in patients with liver disease are described based on recent evidence. We summarize the five sequential steps of the traditional diagnostic approach: 1) confirm true hypotonic hyponatremia, 2) assess the severity of hyponatremia symptoms, 3) measure urine osmolality, 4) classify hyponatremia based on the urine sodium concentration and extracellular fluid status, and 5) rule out any coexisting endocrine disorder and renal failure. Distinct treatment strategies for hyponatremia in liver disease should be applied according to the symptoms, duration, and etiology of disease. Symptomatic hyponatremia requires immediate correction with 3% saline. Asymptomatic chronic hyponatremia in liver disease is prevalent and treatment plans should be individualized based on diagnosis. Treatment options for correcting hyponatremia in advanced liver disease may include water restriction; hypokalemia correction; and administration of vasopressin antagonists, albumin, and 3% saline. Safety concerns for patients with liver disease include a higher risk of osmotic demyelination syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
- Department of Internal Medicine, Seoul University Bundang Hospital, Seongnam, Korea.
- Center for Artificial Intelligence in Healthcare, Seoul University Bundang Hospital, Seongnam, Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Ryu, J. Y., Baek, S. H., & Kim, S. (2023). Evidence-based hyponatremia management in liver disease. Clinical and Molecular Hepatology, 29(4), 924-944. https://doi.org/10.3350/cmh.2023.0090
Vancouver
Ryu JY, Baek SH, Kim S. Evidence-based hyponatremia management in liver disease. Clinical and Molecular Hepatology. 2023;29(4):924-944. doi:10.3350/cmh.2023.0090
BibTeX
@article{Ryu2023,
author = {Ryu, Ji Young and Baek, Seon Ha and Kim, Sejoong},
title = {Evidence-based hyponatremia management in liver disease},
journal = {Clinical and Molecular Hepatology},
year = {2023},
volume = {29},
number = {4},
pages = {924--944},
doi = {10.3350/cmh.2023.0090}
}
EUVIMED